# Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

> **NCT00004065** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Bladder Cancer
- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Head and Neck Cancer
- Kidney Cancer
- Leukemia
- Lung Cancer
- Melanoma (Skin)
- Ovarian Cancer
- Prostate Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** tanespimycin

## Key facts

- **NCT ID:** NCT00004065
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004065, "Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*